Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and microbiome dynamics of SER-287 in mild-to-moderate ulcerative colitis completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SER-287 (SER-287)

Snippet

Sponsor: Seres Therapeutics, Inc. | Conditions: Ulcerative Colitis | Phase 1 | Status: COMPLETED | Results posted: 2019-06-20